References
- Parisi M, Manni A, Caputo F, Trojano M, Paolicelli D. A case report of
late-onset atypical Hemolytic Uremic Syndrome during interferon-beta
in multiple sclerosis: Open issues in literature review. Brain
Behav . 2021 ; 11(1) :e01930.
- Caprioli J, Remuzzi G, Noris M. Thrombotic microangiopathies: from
animal models to human disease and cure. Contrib Nephrol .
2011 ; 169:337-350.
- Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura.Blood . 2017 ; 129(21) :2836-2846.
- Jlajla H, Denman F, Jallouli M, et al. Molecular basis of complement
factor I deficiency in Tunisian atypical hemolytic and uraemic
syndrome patients. Nephrology (Carlton) . 2019 ; 24(3) :357-364.
- Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C ; Groupe
D’stude Des Nephrologues D’ile-de-France (GENIF).
Alpha-interferon-associated thrombotic microangiopathy: a
clinicopathologic study of 8 patients and review of the literature.Medicine (Baltimore) . 2002 ; 81(4) :321-331.
- Walther EU, Hohlfeld R. Multiple sclerosis : side effects of
interferon-beta therapy and their management. Neurology . 1999 ;
53(8) :1622-1627.
- Broughton A, Cosyns JP, Jadoul M. Thrombotic microangiopathy induced
by long-term interferon-β therapy for multiple sclerosis: a case
report. Clin Nephrol . 2011 ; 76(5) :396-400.
- Yam C, Fok A, Mclean C, Butler E, Kempster P. Interferon-beta in
multiple sclerosis causing thrombotic microangiopathy. Intern
Med J . 2019 ; 49(2) :274-276.
- Fox LC, Coney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, et al.
Consensus opinion on diagnosis and management of thrombotic
microangiopathy in Australia and New Zealand. Intern Med J .
2018 ; 48:624-36.
- Loirat C, FréOrganicBacchi V. Atypical hemolytic uremic syndrome.Orphanet J Rare Dis .2011 ; 6: 60.
- de Malmanche T. Routine complement blood tests are insensitive for
alternative complement activation. Intern Med J . 2019 ;
49(8) :1057-1058.
- Orvain C, Augusto JF, Besson V, et al. Thrombotic microangiopathy due
to acquired ADAMTS13 deficiency in a patient receiving interferon-beta
treatment for multiple sclerosis. Int Urol Nephrol . 2014 ;
46(1) :239-242.
- Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM. Complement
factor I in health and disease. Mol Immunol . 2011 ;
48(14) :1611-1620.
- Gerischer, L. M., Siebert, E., Janke, O., Jungehuelsing, G. J., &
Ruprecht, K. (2016). Favorable outcome of interferon-beta associated
thrombotic microangiopathy following treatment with corticosteroids,
plasma exchange and rituximab: A case report. Multiple sclerosis
and related disorders , 10 , 63–65.